www.ompharma.com
Open in
urlscan Pro
54.246.147.143
Public Scan
Submitted URL: https://omedicamed.ch/
Effective URL: https://www.ompharma.com/home
Submission: On September 15 via api from CH — Scanned from CH
Effective URL: https://www.ompharma.com/home
Submission: On September 15 via api from CH — Scanned from CH
Form analysis 0 forms found in the DOM
Text Content
Skip to main content * The new OM Pharma * Global Partnering * Geneva Biotech Center ABOUT US OUR FOCUS PRODUCTS CAREERS MEDIA * * ABOUT US COMPANY Who we are Our history Vision & mission Values Company material THE NEW OM PHARMA Project origin Entrepreneurial shareholders Our investment plan Our visual identity ORGANISATION Board of Directors Executive Committee Scientific and Industrial Advisors GENEVA BIOTECH CENTER Our Biotech Center Know-how Industrial development capabilities International export expertise GLOBAL PARTNERING Strategic partnerships as business model Our presence across the world Our main partners Sustainable and profitable partnership OUR FOCUS THERAPEUTIC AREAS Infectious diseases Vascular diseases RESEARCH AND DEVELOPMENT Bacterial lysates New molecules R&D pipeline Main scientific collaborations Our trials Investigator initiated studies PATIENTS Patient testimonials Patient awareness PRODUCTS PRODUCTS Our global products Our Swiss products CAREERS CAREERS Working at OM Pharma Career openings Students Get in touch with our team MEDIA MEDIA News Media presence Media contact Social media Multimedia Resources WELCOME TO OM PHARMA A global Geneva-based biopharmaceutical company, leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases. A global Geneva-based biopharmaceutical company DISCOVER MORE OUR GLOBAL THERAPEUTIC AREAS INFECTIOUS DISEASES Our products - based on oral, lyophilized bacterial extracts - stimulate the immune system. LEARN MORE VASCULAR DISEASES Our products treat vascular disorders, microangiopathies and capillary hemorrhages. LEARN MORE OUR SWISS THERAPEUTIC AREAS OUR SWISS AFFILIATE The Swiss affiliate has a wide range of owned and in-licensed products in four areas of expertise: Respiratory, Urology/Gynaecology, Central Nervous System and Vascular Diseases. LEARN MORE Etienne Jornod Executive Chairman & Co‑Owner > We are excited to further expand OM Pharma, creating a highly attractive > biopharmaceutical company focused on improving the lives of patients with > respiratory and inflammatory diseases. > > ” Roch Ogier Chief Executive Officer > With our unique knowledge and the tremendous commitment of our employees, I am > confident that we will make great strides in both the scientific and > commercial development of our products, changing the way physicians and > patients approach immunity > > ” LATEST NEWS OM-85-IN: FIRST PARTICIPANT DOSED 25 July 2024 PRESS RELEASE Initiation of Phase 1a/b with the first human administration of the intranasal form of OM-85, a bacterial lysate and immune system modulator, already approved in oral form for the prevention of recurrent respiratory tract infections. READ MORE OM PHARMA SUISSE ENTERS INTO AGREEMENT WITH JANSSEN SWITZERLAND 07 February 2024 BUSINESS NEWS OM Pharma Suisse SA enters into agreement with Janssen Switzerland for the exclusive distribution of Xeplion® and Trevicta® in Switzerland. READ MORE NEW CEO 06 December 2023 PRESS RELEASE OM Pharma’s Board of Directors has appointed Roch Ogier as Chief Executive Officer (CEO) with effect from January 1, 2024. READ MORE IND APPLICATION 14 December 2022 PRESS RELEASE OM Pharma successfully submitted an IND application to the FDA READ MORE OFFICE OPENING 11 October 2022 BUSINESS NEWS OM Pharma opens a new office in Shanghai READ MORE NEW PARTNERSHIP 05 September 2022 BUSINESS NEWS OM Pharma and Medinfar enter into exclusive agreement to promote Broncho-Vaxom® in Portugal READ MORE OM-85 AND ATOPIC DERMATITIS 27 July 2022 SCIENTIFIC NEWS An in-silico clinical trial model for children with Atopic Dermatitis suggested a subset of immunological biomarkers predictive of response to OM-85 READ MORE SUCCESS STORIES AWARD 2022 03 May 2022 PRESS RELEASE Etienne Jornod, OM Pharma‘s Executive Chairman receives Swiss Biotech Success Stories Award 2022 READ MORE OM-85 AND SARS-COV-2 01 December 2021 SCIENTIFIC NEWS An in-vitro study concludes that the bacterial extract OM-85 reduces the binding of SARS-CoV-2 on human bronchial epithelial cells READ MORE OM-85-IN: FIRST PARTICIPANT DOSED 25 July 2024 PRESS RELEASE Initiation of Phase 1a/b with the first human administration of the intranasal form of OM-85, a bacterial lysate and immune system modulator, already approved in oral form for the prevention of recurrent respiratory tract infections. READ MORE OM PHARMA SUISSE ENTERS INTO AGREEMENT WITH JANSSEN SWITZERLAND 07 February 2024 BUSINESS NEWS OM Pharma Suisse SA enters into agreement with Janssen Switzerland for the exclusive distribution of Xeplion® and Trevicta® in Switzerland. READ MORE NEW CEO 06 December 2023 PRESS RELEASE OM Pharma’s Board of Directors has appointed Roch Ogier as Chief Executive Officer (CEO) with effect from January 1, 2024. READ MORE IND APPLICATION 14 December 2022 PRESS RELEASE OM Pharma successfully submitted an IND application to the FDA READ MORE OFFICE OPENING 11 October 2022 BUSINESS NEWS OM Pharma opens a new office in Shanghai READ MORE NEW PARTNERSHIP 05 September 2022 BUSINESS NEWS OM Pharma and Medinfar enter into exclusive agreement to promote Broncho-Vaxom® in Portugal READ MORE OM-85 AND ATOPIC DERMATITIS 27 July 2022 SCIENTIFIC NEWS An in-silico clinical trial model for children with Atopic Dermatitis suggested a subset of immunological biomarkers predictive of response to OM-85 READ MORE SUCCESS STORIES AWARD 2022 03 May 2022 PRESS RELEASE Etienne Jornod, OM Pharma‘s Executive Chairman receives Swiss Biotech Success Stories Award 2022 READ MORE OM-85 AND SARS-COV-2 01 December 2021 SCIENTIFIC NEWS An in-vitro study concludes that the bacterial extract OM-85 reduces the binding of SARS-CoV-2 on human bronchial epithelial cells READ MORE OM-85-IN: FIRST PARTICIPANT DOSED 25 July 2024 PRESS RELEASE Initiation of Phase 1a/b with the first human administration of the intranasal form of OM-85, a bacterial lysate and immune system modulator, already approved in oral form for the prevention of recurrent respiratory tract infections. READ MORE OM PHARMA SUISSE ENTERS INTO AGREEMENT WITH JANSSEN SWITZERLAND 07 February 2024 BUSINESS NEWS OM Pharma Suisse SA enters into agreement with Janssen Switzerland for the exclusive distribution of Xeplion® and Trevicta® in Switzerland. READ MORE NEW CEO 06 December 2023 PRESS RELEASE OM Pharma’s Board of Directors has appointed Roch Ogier as Chief Executive Officer (CEO) with effect from January 1, 2024. READ MORE IND APPLICATION 14 December 2022 PRESS RELEASE OM Pharma successfully submitted an IND application to the FDA READ MORE OFFICE OPENING 11 October 2022 BUSINESS NEWS OM Pharma opens a new office in Shanghai READ MORE NEW PARTNERSHIP 05 September 2022 BUSINESS NEWS OM Pharma and Medinfar enter into exclusive agreement to promote Broncho-Vaxom® in Portugal READ MORE OM-85 AND ATOPIC DERMATITIS 27 July 2022 SCIENTIFIC NEWS An in-silico clinical trial model for children with Atopic Dermatitis suggested a subset of immunological biomarkers predictive of response to OM-85 READ MORE SUCCESS STORIES AWARD 2022 03 May 2022 PRESS RELEASE Etienne Jornod, OM Pharma‘s Executive Chairman receives Swiss Biotech Success Stories Award 2022 READ MORE OM-85 AND SARS-COV-2 01 December 2021 SCIENTIFIC NEWS An in-vitro study concludes that the bacterial extract OM-85 reduces the binding of SARS-CoV-2 on human bronchial epithelial cells READ MORE JOIN OM PHARMA We offer a vibrant workplace culture and development opportunities and are dedicated to employee and business success. Discover this culture and our career opportunities. LEARN MORE WATCH OUR CORPORATE VIDEO This website uses cookies to improve your experience. We use necessary cookies for the functionality of our website, as well as optional cookies for analytical and performance purposes. Collecting and reporting information via optional cookies helps us improve your experience. To read more - or decline the use of some cookies - please see our Cookie Policy. COOKIE SETTINGSACCEPT ALL CONNECT WITH US * * CONTACT US * © 2021 OM Pharma Ltd. * TERMS AND CONDITIONS * LEGAL NOTICE * TERMS OF USE * PRIVACY POLICY * COOKIE POLICY * COOKIE SETTING * SITE MAP